>

NanoSyrinx highlighted in Cell Trends

Our CEO Joe Healey was recently invited to write a piece for Cell Trends’ “Industry Highlights”, which is now available online here.

These articles offer short reads about up and coming companies and technologies that are making waves in the industry. NanoSyrinx is delighted to have had the opportunity to tell our story.

The article explains why biologics are of significant pharmaceutical interest, as well as the big problems facing their utilisation – namely, drug delivery. Read on if you would like to learn more about why these classes of molecules are so promising, where NanoSyrinx believes it can help address the outstanding challenges, and to get a sense of just how successful these modalities have been already.

Read more news

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines          

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials […]

Read more
Nature Biopharma Dealmakers figure of the NanoSyrinx platform

NanoSyrinx featured in Nature Biopharma Dealmakers

NanoSyrinx is delighted to have been featured in Nature’s Biopharma Dealmakers in an in-depth article exploring how the company is engineering bacterial nanomachines into a new therapeutic modality for targeted intracellular protein delivery. The article highlights NanoSyrinx’s progress in tackling the longstanding challenge that >80% of intracellular targets remain undruggable, our platform’s ability to deliver […]

Read more
Dr Valentina Galli

NanoSyrinx strengthens senior R&D team

Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today […]

Read more